News
SRNE
--
0.00%
--
Sorrento Publishes Abivertinib Teaser Entitled 'Abivertinib – A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases'
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced the publication of a Teaser titled "Abivertinib – a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune
Benzinga · 12h ago
COVID-19 Vaccine stocks/Biotechs surge on worries over new COVID-19 variant
U.S. vaccine makers are trading higher premarket amid rising fears over new COVID-19 variant identified in South Africa. Shares of Pfizer (NYSE:PFE), up 6.1% and BioNTech (NASDAQ:BNTX), jumping 7.6% also got boost after the
Seekingalpha · 3d ago
BRIEF-Sorrento Therapeutics Mexico Executes Contract For Sale Of 5 Million COVI-STIX Tests For Mexico Market
reuters.com · 11/22 20:14
Sorrento Therapeutics Reports Mexico Has Executed Contract For Sale Of 5M Of Co.'s COVI-STIX Tests For Mexican Market, No Terms Disclosed
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, &ldquo, Sorrento&rdquo, )) announced today its subsidiary, Sorrento Therapeutics Mexico, has executed a contract with a leading local distributor for the sale and distribution of
Benzinga · 11/22 19:55
Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market
SAN DIEGO and MEXICO CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary,...
Globe Newswire · 11/22 19:53
With Progress on Multiple Fronts, Sorrento Stock Is a Great Buy: Analyst
Sorrento Therapeutics (SRNE) has plans to shortly advance its Bruton’s tyrosine kinase (Btk) inhibitor abivertinib into pivotal testing for the treatment of hospitalized COVID-19-infected patients, yet abivertinib has recently been making waves as a possib...
TipRanks · 11/16 22:17
Sorrento Therapeutics Granted U.S. Patent Titled 'Anti-KRAS binding proteins'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5081&f=G&l=50&d=PTXT&p=102&S1=20211116&OS=20211116&RS=20211116
Benzinga · 11/16 15:22
Sorrento Therapeutics Mexico To Partner With World Boxing Council For Screening Of COVID-19 Of All Convention Attendees with COVI-STIX At The 59th World Boxing Council Convention In Mexico City
Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))) and the World Boxing Council ("WBC") announced today that Sorrento's COVI-STIX COVID-19 Virus Rapid Antigen Detection Test
Benzinga · 11/12 20:22
Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City
SAN DIEGO and MEXICO CITY, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento’s COVI-STIX COVID-19 Virus Rapid Antigen Detection Test (“COVI-STIX”) wil...
GlobeNewswire · 11/12 20:19
BRIEF-Sorrento Announces Publication Of Pivotal Trial Results Of Non-Small Cell Lung Cancer Treatment
reuters.com · 11/12 14:16
DYAI: Two New Deals & A Pharma in the Wings
By John Vandermosten, CFA NASDAQ:DYAI NASDAQ:SRNE READ THE FULL DYAI RESEARCH REPORT Third Quarter 2021 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) released third quarter 2021 operational and financial results on November 10, 20...
Zacks Small Cap Research · 11/11 13:00
Sorrento Awarded California Competes Tax Credit
SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”) bet...
GlobeNewswire · 11/07 18:08
Sorrento issued regulatory nod for rapid COVID-19 test in Brazil
Sorrento Therapeutics (SRNE +2.3%) announced that the national agency for approval of food, cosmetics, and medical devices (ANVISA) in Brazil has authorized COVISTIX, a rapid diagnostic test for the detection
Seekingalpha · 11/03 17:04
BRIEF-Sorrento Receives Brazilian Health Regulatory Agency Approval For Covistix™ For Brazil
reuters.com · 11/03 16:55
Sorrento Therapeutics Reports Received Brazilian Health Regulatory Agency Approval For COVISTIX Antigen Test In Brazil
COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in Brazil.   Commercialization in progress with
Benzinga · 11/03 14:07
Sorrento Receives Brazilian Health Regulatory Agency (ANVISA) Approval for COVISTIX™ (COVID-19 Virus Antigen Detection Test) for Brazil
COVISTIX now approved for point of care use in symptomatic patients by ANVISA (national agency for approval of food, cosmetics, and medical devices) in...
Globe Newswire · 11/03 14:06
Sorrento Therapeutics Secures Brazil's Approval For Covistix COVID-19 Test; Shares Climb
MT Newswires · 11/03 11:07
BRIEF-Sorrento's License Partner, Lee's Pharma Announces NDA Filing Acceptance By NMPA For Anti-PD-L1 Antibody Socazolimab For Metastatic Cervical Cancer Treatment
reuters.com · 11/01 13:46
Sorrento’s license partner submits socazolimab NDA in China for cervical cancer
Sorrento Therapeutics (NASDAQ:SRNE) license partner China Oncology Focus has submitted a new drug application for socazolimab for the greater China territory to treat recurrent or metastatic cervical cancer. China Oncology Focus is an
Seekingalpha · 11/01 13:14
Webull provides a variety of real-time SRNE stock news. You can receive the latest news about Sorrento Thera through multiple platforms. This information may help you make smarter investment decisions.
About SRNE
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its proprietary G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company's multimodal, multipronged approach to fighting cancer is made possible by immuno-oncology platforms, including key assets such as fully human antibodies, clinical-stage immuno-cellular therapies, antibody-drug conjugates, and clinical-stage oncolytic virus. It is also developing potential antiviral therapies and vaccines against coronaviruses, which includes COVI-GUARD, COVI-AMG, COVI-SHIELD, Gene-MAb, COVI-MSC, and COVI-DROPS.